Want to join the conversation?
$FRED now expects 2016 total sales to increase 2-6% and comparable store sales to increase 1-4%. The change in outlook is primarily driven by the industry-wide slowdown in the Hepatitis C specialty drug market. EPS for 2016 are expected to $0.27-0.32 range. Adjusted EBITDA is forecasted to be $73-78MM, an increase of 35-45%.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.